<DOC>
	<DOCNO>NCT01522729</DOCNO>
	<brief_summary>Recently , direct evidence point contribute role peripheral muscle fatigue exercise tolerance among patient COPD . However , physiological mechanism peripheral muscle fatigue impairs exercise tolerance still unknown , factor regulate peripheral muscle fatigue COPD may complex . One possible link limb muscle fatigue exercise intolerance could enhance afferent signal active limb muscle central command , thereby limit central motor output eventually leading exercise termination . A direct method investigate regulation peripheral muscle fatigue exercise patient COPD blockade peripheral neural afferent via lumbar anesthesia . Consequently , investigate interplay peripheral muscular component central motor command self-paced exercise could shed light regulation peripheral muscle fatigue COPD implication exercise intolerance .</brief_summary>
	<brief_title>Impact Muscle Afferent Feedback During Exercise Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>The aim study characterize role peripheral muscle afferent development muscle fatigue , cardiorespiratory response exercise tolerance constant-workrate endurance cycling exercise patient COPD . In double-blind randomized design , patient GOLD stage II-III COPD recruit complete constant-workrate cycle test follow either injection placebo [ NaCl , interspinous L2-L3 ] opioid [ Fentanyl 25 Âµg , intrathecal L2-L3 ] inhibit central feedback peripheral muscle sensory afferent . Quadriceps force ( TwQ ) measure magnetic stimulation femoral nerve central chemoreceptor response assess CO2 rebreathing , perform injection . Finally , TwQ also measure endurance cycle test ass magnitude quadriceps fatigue induced symptom-limited exercise .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Smoking history &gt; 15 packyears COPD GOLD IIIII ( 30 % predict &lt; FEV1 &lt; 80 % predict ; FEV1/FVC &lt; 0.70 ) Unstable condition Recent exacerbation ( &lt; 3 month ) Recent cancer ( &lt; 3 month ) Myopathy , neuromuscular disease Unstable cardiac disease Hepatic , kidney , intestinal disease BMI &gt; 35 PaCO2 &gt; 45 mmHg PaO2 &lt; 60 mmHg</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Chronic pulmonary obstructive disease</keyword>
	<keyword>Muscle dysfunction</keyword>
	<keyword>Exercise intolerance</keyword>
	<keyword>Muscle afferent</keyword>
	<keyword>Ventilation</keyword>
</DOC>